A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Clinical trial NCT06830889 · RECRUITING
Trial details
- NCT number
- NCT06830889
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-03
- Primary completion
- 2031-10-01
- Enrollment
- 1450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.